Literature DB >> 27356249

The Impact on Life questionnaire: validation for elective surgery prioritisation in New Zealand prioritisation criteria in orthopaedic surgery.

Georgina Chan, Louret Bezuidenhout, Logan Walker, Robert Rowan1.   

Abstract

AIM: This cohort study tested the reliability and validity of the Impact on Life (IoL) patient-rated questionnaire for use in prioritising orthopaedic procedures.
METHODS: Three hundred and twenty-four patients completed the questionnaire during specialist orthopaedic assessments over a 5-month period in 2013. The reliability and validity of the IoL were tested against the SF-12 and Oxford scores. Correlation analysis was used to assess patient- and surgeon-rated scores. Internal consistency reliability was assessed using Cronbach's alpha. Patient- and surgeon-rated scores were further analysed between patients added to the waiting list and those that were not.
RESULTS: Participants' mean age was 58 years (range 18-88). Reliability analysis showed the IoL had excellent internal consistency with a Cronbach's alpha of 0.926, reaching the threshold for clinical application. Construct validity of the IoL was confirmed with significant correlation with other validated quality of life measures (p<0.01). T-tests indicated that patients placed on the waiting list had significantly higher surgeon and IoL scores (p<0.001), compared with those not placed on the waiting list.
CONCLUSION: Our results support the IoL as a valid and reliable method of assessing patient-rated quality of life and recommend its use in the Orthopaedic Clinical Priority Assessment Criteria score.

Entities:  

Mesh:

Year:  2016        PMID: 27356249

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  1 in total

1.  Geographical and ethnic differences of osteoarthritis-associated hip and knee replacement surgeries in New Zealand: a population-based cross-sectional study.

Authors:  Chunhuan Lao; David Lees; Sandeep Patel; Douglas White; Ross Lawrenson
Journal:  BMJ Open       Date:  2019-09-20       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.